Selected research
Industry Research
Rifampicin Industry Research Report 2026
Market perspective
The global Rifampicin market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Rifampicin is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Rifampicin is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Rifampicin is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Rifampicin include Sanofi, Hebei Xingang Pharmaceutical, Wellona Pharma, Mercator Pharmaceutical Solutions, AVANSCURE LIFESCIENCES and ASIAN PHARMACY, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Rifampicin market in terms of revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Rifampicin Market by Company
Sanofi
Hebei Xingang Pharmaceutical
Wellona Pharma
Mercator Pharmaceutical Solutions
AVANSCURE LIFESCIENCES
ASIAN PHARMACY
Rifampicin Segment by Type
Oral
Intravenous Injection
Rifampicin Segment by Application
Leprosy
Legionnaire's Disease
Tuberculosis
Others
Rifampicin Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rifampicin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rifampicin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rifampicin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Rifampicin manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Rifampicin by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Rifampicin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Intravenous Injection
Applications
- Leprosy
- Legionnaire's Disease
- Tuberculosis
- Others
Companies covered
- Sanofi
- Hebei Xingang Pharmaceutical
- Wellona Pharma
- Mercator Pharmaceutical Solutions
- AVANSCURE LIFESCIENCES
- ASIAN PHARMACY
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Rifampicin Market Size (2021-2032)
- 2.2.2 Global Rifampicin Sales (2021-2032)
- 2.2.3 Global Rifampicin Market Average Price (2021-2032)
- 2.3 Rifampicin by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Oral
- 2.3.3 Intravenous Injection
- 2.4 Rifampicin by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Leprosy
- 2.4.3 Legionnaire's Disease
- 2.4.4 Tuberculosis
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Rifampicin Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Rifampicin Sales (Tons) of Manufacturers (2021-2026)
- 3.3 Global Rifampicin Revenue of Manufacturers (2021-2026)
- 3.4 Global Rifampicin Average Price by Manufacturers (2021-2026)
- 3.5 Global Rifampicin Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Rifampicin, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Rifampicin, Product Type & Application
- 3.8 Global Manufacturers of Rifampicin, Established Date
- 3.9 Global Rifampicin Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sanofi
- 4.1.1 Sanofi Company Information
- 4.1.2 Sanofi Business Overview
- 4.1.3 Sanofi Rifampicin Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sanofi Rifampicin Product Portfolio
- 4.1.5 Sanofi Recent Developments
- 4.2 Hebei Xingang Pharmaceutical
- 4.2.1 Hebei Xingang Pharmaceutical Company Information
- 4.2.2 Hebei Xingang Pharmaceutical Business Overview
- 4.2.3 Hebei Xingang Pharmaceutical Rifampicin Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Hebei Xingang Pharmaceutical Rifampicin Product Portfolio
- 4.2.5 Hebei Xingang Pharmaceutical Recent Developments
- 4.3 Wellona Pharma
- 4.3.1 Wellona Pharma Company Information
- 4.3.2 Wellona Pharma Business Overview
- 4.3.3 Wellona Pharma Rifampicin Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Wellona Pharma Rifampicin Product Portfolio
- 4.3.5 Wellona Pharma Recent Developments
- 4.4 Mercator Pharmaceutical Solutions
- 4.4.1 Mercator Pharmaceutical Solutions Company Information
- 4.4.2 Mercator Pharmaceutical Solutions Business Overview
- 4.4.3 Mercator Pharmaceutical Solutions Rifampicin Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Mercator Pharmaceutical Solutions Rifampicin Product Portfolio
- 4.4.5 Mercator Pharmaceutical Solutions Recent Developments
- 4.5 AVANSCURE LIFESCIENCES
- 4.5.1 AVANSCURE LIFESCIENCES Company Information
- 4.5.2 AVANSCURE LIFESCIENCES Business Overview
- 4.5.3 AVANSCURE LIFESCIENCES Rifampicin Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 AVANSCURE LIFESCIENCES Rifampicin Product Portfolio
- 4.5.5 AVANSCURE LIFESCIENCES Recent Developments
- 4.6 ASIAN PHARMACY
- 4.6.1 ASIAN PHARMACY Company Information
- 4.6.2 ASIAN PHARMACY Business Overview
- 4.6.3 ASIAN PHARMACY Rifampicin Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 ASIAN PHARMACY Rifampicin Product Portfolio
- 4.6.5 ASIAN PHARMACY Recent Developments
5 Global Rifampicin Market Scenario by Region
- 5.1 Global Rifampicin Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Rifampicin Sales by Region: 2021-2032
- 5.2.1 Global Rifampicin Sales by Region: 2021-2026
- 5.2.2 Global Rifampicin Sales by Region: 2027-2032
- 5.3 Global Rifampicin Revenue by Region: 2021-2032
- 5.3.1 Global Rifampicin Revenue by Region: 2021-2026
- 5.3.2 Global Rifampicin Revenue by Region: 2027-2032
- 5.4 North America Rifampicin Market Facts & Figures by Country
- 5.4.1 North America Rifampicin Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Rifampicin Sales by Country (2021-2032)
- 5.4.3 North America Rifampicin Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Rifampicin Market Facts & Figures by Country
- 5.5.1 Europe Rifampicin Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Rifampicin Sales by Country (2021-2032)
- 5.5.3 Europe Rifampicin Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Rifampicin Market Facts & Figures by Country
- 5.6.1 Asia Pacific Rifampicin Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Rifampicin Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Rifampicin Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Rifampicin Market Facts & Figures by Country
- 5.7.1 South America Rifampicin Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Rifampicin Sales by Country (2021-2032)
- 5.7.3 South America Rifampicin Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Rifampicin Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Rifampicin Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Rifampicin Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Rifampicin Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Rifampicin Sales by Type (2021-2032)
- 6.1.1 Global Rifampicin Sales by Type (2021-2032) & (Tons)
- 6.1.2 Global Rifampicin Sales Market Share by Type (2021-2032)
- 6.2 Global Rifampicin Revenue by Type (2021-2032)
- 6.2.1 Global Rifampicin Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Rifampicin Revenue Market Share by Type (2021-2032)
- 6.3 Global Rifampicin Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Rifampicin Sales by Application (2021-2032)
- 7.1.1 Global Rifampicin Sales by Application (2021-2032) & (Tons)
- 7.1.2 Global Rifampicin Sales Market Share by Application (2021-2032)
- 7.2 Global Rifampicin Revenue by Application (2021-2032)
- 7.2.1 Global Rifampicin Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Rifampicin Revenue Market Share by Application (2021-2032)
- 7.3 Global Rifampicin Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Rifampicin Value Chain Analysis
- 8.1.1 Rifampicin Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Rifampicin Production Mode & Process
- 8.2 Rifampicin Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Rifampicin Distributors
- 8.2.3 Rifampicin Customers
9 Global Rifampicin Analyzing Market Dynamics
- 9.1 Rifampicin Industry Trends
- 9.2 Rifampicin Industry Drivers
- 9.3 Rifampicin Industry Opportunities and Challenges
- 9.4 Rifampicin Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst